Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Arbutus Biopharma Corporation

< Previous 1 2 Next >
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS BRNS
Arbutus to Present at Jefferies London Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Participate in Two Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Appoints Two New Executives
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS BMY KRYS NBRV
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS VACC
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Present at Jefferies Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Present at JMP Securities Life Sciences Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS BNTX PFE
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Tickers ABUS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.